RecruitingNCT06320223

PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer

PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer

Sponsor

University Hospital, Essen

Enrollment

10,000 participants

Start Date

Mar 5, 2024

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer Survivorship PET/CT PSMA

Summary

Background: PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. Need: Improved prognostication across various stages of prostate cancer is needed for management guidance and study design. Aim: 1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a registry study tracking outcomes for prostate cancer patients who have had a type of PET scan called PSMA-PET — an advanced imaging test that uses a radioactive tracer to find prostate cancer cells throughout the body. The study collects data on how these scans influence treatment decisions and long-term survival. **You may be eligible if...** - You are an adult with a biopsy-confirmed diagnosis of prostate cancer - You have had a PSMA-PET scan for staging or re-staging at any point in your care - You have at least 3 years of survival follow-up data available **You may NOT be eligible if...** - You have a neuroendocrine subtype of prostate cancer - You have another active metastatic cancer (other than prostate cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

University Hospital Essen

Essen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06320223

Related Trials

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

DESTINY-PANTUMOUR04

NCT0712400017 locations